135.1 ð é«åžçç
135.1.0.1 ð äžé éé»
- Acute monoarthritis = septic arthritis until proven otherwise (rule out gout/CPPD)
- Joint aspiration is essential: cell count, Gram, culture, crystal
- ç
å:
- Adult: S. aureus (#1), S. pyogenes, S. pneumoniae, Gram - (HCAI, immunocompromised)
- Sexually active adults: N. gonorrhoeae (Disseminated Gonococcal Infection)
- Children: K. kingae (< 4 yo), S. aureus, S. pyogenes
- Prosthetic joint: CoNS, S. aureus
- Animal bite: Pasteurella (cat), Eikenella (human)
- Tick-bite (US): Borrelia burgdorferi (Lyme)
- Empirical: Vancomycin + Ceftriaxone (cover MRSA + GN + DGI)
- Drainage + 2-4 weeks IV antibiotic (longer for prosthetic / Mycobacterium / fungi)
135.1.0.2 1ïžâ£ Joint Aspiration â Synovial Fluid Analysis
ð äžææŠå¿µèªªæïŒJoint aspiration æ¯ septic arthritis çééµåäœïŒè¶æ©æœè¶å¥œãé·é±ïŒcrystals (gout/CPPD) è septic arthritis å¯åæååš â çå°çµæ¶äžèœæŸå¿ïŒå¿ é Gram + culture confirmãSynovial WBC > 50,000 + PMN > 75% æ¯ septic äž»èŠ cutoffïŒäœæäº septic case WBC èŒäœïŒèšåºé«åºŠæ·çå°±èŠç¶ septic æ²»ç, äžèœå®çæžåãGlucose 倧é (vs serum) æ¯åŠäžå supporting clueãéé»é åºïŒ(1) æœæ¶² â (2) ç«å³ Gram stain (40-50% éœæ§) + culture éã(3) WBC + diff + crystal + glucoseã(4) äžèŠççµæç«å» empirical Vanco + Ceftriaxone + drainã
| Parameter | Normal | Inflammatory | Septic | Crystal |
|---|---|---|---|---|
| Color | Clear | Yellow | Cloudy/purulent | Yellow |
| WBC | < 200/ÎŒL | 2,000-50,000 | > 50,000 (often 100K+) | Variable, often > 50K (overlap!) |
| PMN% | < 25% | > 50% | > 75-90% | > 50% |
| Glucose | Equal serum | Slightly low | Often very low | Normal |
| Crystals | None | None | None (usually) | MSU (gout) or CPPD (pseudogout) |
| Gram + culture | None | None | Positive ~40-50% Gram, 90% culture | None |
â ïž Crystals + septic å¯åæååš â å¿ é gram + culture confirm
135.1.0.3 2ïžâ£ ç å + Empirical
135.1.0.3.1 Native Joint, Healthy Adult
| é¢šéª | ç å |
|---|---|
| Default (sexually active) | N. gonorrhoeae (DGI) + S. aureus + Strep |
| Older / immunocompromised / IVDU | S. aureus (incl MRSA) + GN |
| Crystalline diagnosis: but septic until proven |
135.1.0.3.2 Empirical Treatment
- Vancomycin + Ceftriaxone (covers MRSA + DGI + most pathogens)
- IVDU/HCAI: Vancomycin + Pip-tazo or Cefepime
- After culture: narrow spectrum
135.1.0.3.3 Prosthetic Joint
- Acute (< 3 mo post-op): S. aureus, GNs
- Late: CoNS, S. aureus, S. viridans
- Treatment: 1-2 stage revision + antibiotic 6-8 weeks (++ rifampin for staph)
135.1.0.3.4 Disseminated Gonococcal Infection (DGI)
- 1-3% gonorrhea â DGI
- Triad (varied):
- Tenosynovitis (asymmetric, hands/feet/wrist/ankle)
- Migratory polyarthralgia (transient)
- Dermatitis (pustular/papular skin lesions)
- Often Joint aspiration culture-negative (~ 50%)
- PCR of urethra, cervix, throat, rectum â é« yield
- Treatment: Ceftriaxone 1g IV daily à 7-14 d, then PO step-down
- + Doxycycline or Azithromycin to cover concomitant Chlamydia
135.1.0.4 3ïžâ£ Drainage + æçº
135.1.0.5 4ïžâ£ Special Causes
135.1.0.5.1 Lyme Arthritis
- Borrelia burgdorferi (US northeast/midwest, EU, increasingly worldwide)
- Late manifestation (months after EM rash, untreated)
- Mono- or oligoarthritis of large joints (knee most), recurrent
- Diagnosis: serology (ELISA â Western blot, two-tier)
- Treatment: doxycycline 100 mg BID Ã 28 d (oral); ceftriaxone IV if neuro/refractory
135.1.0.5.2 Tuberculosis Arthritis
- Hematogenous from primary TB (often years later)
- Mono-arthritis, slow progression, often spine (Pottâs disease) > peripheral joints
- Diagnosis: synovial biopsy + AFB culture + GeneXpert MTB
- Treatment: 4-drug RIPE Ã 2 mo + 7 mo INH/RIF (= 9 month total)
135.1.0.5.3 Fungal Arthritis
- Candida: prosthetic joint, CRBSI, IVDU
- Sporotrichosis: gardener (rose thorn)
- Coccidioides, Histoplasma, Blastomyces: endemic mycosis
- Treatment: amphotericin B â azole; long course (months)
135.1.0.5.4 Reactive Arthritis (Reiterâs)
- Post-infectious (not direct infection): GI (Yersinia, Campylobacter, Salmonella), GU (Chlamydia)
- 1-4 weeks after primary
- Triad: arthritis + uveitis/conjunctivitis + urethritis
- HLA-B27 association
- Treatment: NSAIDs + treat primary infection + DMARDs if persistent